Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
Abstract Background Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung disease. Rapamycin, an inhibitor of fibroblast proliferation could be a potential anti-fibrotic drug to improve...
Main Authors: | M. Molina-Molina, C. Machahua-Huamani, V. Vicens-Zygmunt, R. Llatjós, I. Escobar, E. Sala-Llinas, P. Luburich-Hernaiz, J. Dorca, A. Montes-Worboys |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12890-018-0626-4 |
Similar Items
-
Reactivation pulmonary tuberculosis in two patients treated with pirfenidone
by: Mohammad Khan, et al.
Published: (2017-01-01) -
Perils with Pirfenidone and “the tuberculosis link”
by: Madhav H Hande, et al.
Published: (2019-01-01) -
Antifibrotic activities of pirfenidone in animal models
by: L. Pan, et al.
Published: (2011-06-01) -
Comparative study between pirfenidone and traditional drugs in treatment of idiopathic pulmonary fibrosis
by: Ramadan M Nafee, et al.
Published: (2019-01-01) -
Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study
by: Myung Jin Song, et al.
Published: (2021-05-01)